CN103340835A - 一种适用于婴幼儿及儿童的口腔崩解片及其制备方法 - Google Patents
一种适用于婴幼儿及儿童的口腔崩解片及其制备方法 Download PDFInfo
- Publication number
- CN103340835A CN103340835A CN2013102903287A CN201310290328A CN103340835A CN 103340835 A CN103340835 A CN 103340835A CN 2013102903287 A CN2013102903287 A CN 2013102903287A CN 201310290328 A CN201310290328 A CN 201310290328A CN 103340835 A CN103340835 A CN 103340835A
- Authority
- CN
- China
- Prior art keywords
- oseltamivir
- micropill
- oral cavity
- cavity disintegration
- odor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims description 64
- 239000006191 orally-disintegrating tablet Substances 0.000 title abstract description 6
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 claims abstract description 121
- 229960003752 oseltamivir Drugs 0.000 claims abstract description 103
- 239000003814 drug Substances 0.000 claims abstract description 61
- 239000011230 binding agent Substances 0.000 claims abstract description 43
- 239000000945 filler Substances 0.000 claims abstract description 39
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 35
- 239000004925 Acrylic resin Substances 0.000 claims abstract description 27
- 239000000314 lubricant Substances 0.000 claims abstract description 21
- 235000019640 taste Nutrition 0.000 claims abstract description 20
- 239000002245 particle Substances 0.000 claims abstract description 18
- 239000000463 material Substances 0.000 claims abstract description 14
- 239000006187 pill Substances 0.000 claims abstract description 8
- 150000003839 salts Chemical class 0.000 claims abstract description 6
- 239000004615 ingredient Substances 0.000 claims abstract description 5
- 210000000214 mouth Anatomy 0.000 claims description 86
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 74
- 238000000576 coating method Methods 0.000 claims description 57
- 239000008188 pellet Substances 0.000 claims description 51
- 239000011248 coating agent Substances 0.000 claims description 46
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 41
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 36
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 31
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 31
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 29
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 25
- 229930195725 Mannitol Natural products 0.000 claims description 25
- 239000000594 mannitol Substances 0.000 claims description 25
- 235000010355 mannitol Nutrition 0.000 claims description 25
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 25
- 229930006000 Sucrose Natural products 0.000 claims description 22
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 22
- 235000010357 aspartame Nutrition 0.000 claims description 22
- 239000005720 sucrose Substances 0.000 claims description 22
- 108010011485 Aspartame Proteins 0.000 claims description 19
- 239000000605 aspartame Substances 0.000 claims description 19
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 19
- 229960003438 aspartame Drugs 0.000 claims description 19
- 235000019359 magnesium stearate Nutrition 0.000 claims description 18
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 claims description 17
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 17
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 17
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 17
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 17
- 229920002472 Starch Polymers 0.000 claims description 16
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 16
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 16
- 239000008107 starch Substances 0.000 claims description 16
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 15
- 229960003943 hypromellose Drugs 0.000 claims description 15
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 13
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims description 13
- 235000010603 pastilles Nutrition 0.000 claims description 13
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims description 13
- 235000019698 starch Nutrition 0.000 claims description 13
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 11
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 11
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 11
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 10
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 10
- 241000220223 Fragaria Species 0.000 claims description 9
- 235000016623 Fragaria vesca Nutrition 0.000 claims description 9
- 235000011363 Fragaria x ananassa Nutrition 0.000 claims description 9
- 230000001476 alcoholic effect Effects 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 238000011282 treatment Methods 0.000 claims description 9
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 8
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 8
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 8
- 239000008101 lactose Substances 0.000 claims description 8
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 8
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 8
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 8
- 239000000811 xylitol Substances 0.000 claims description 8
- 235000010447 xylitol Nutrition 0.000 claims description 8
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 8
- 229960002675 xylitol Drugs 0.000 claims description 8
- 239000000796 flavoring agent Substances 0.000 claims description 7
- 238000007373 indentation Methods 0.000 claims description 6
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 5
- 206010022000 influenza Diseases 0.000 claims description 5
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 5
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 claims description 4
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 4
- 239000005715 Fructose Substances 0.000 claims description 4
- 229930091371 Fructose Natural products 0.000 claims description 4
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 4
- 229920002125 Sokalan® Polymers 0.000 claims description 4
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 4
- 238000004132 cross linking Methods 0.000 claims description 4
- 235000013355 food flavoring agent Nutrition 0.000 claims description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 4
- 239000004584 polyacrylic acid Substances 0.000 claims description 4
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims description 4
- 239000011347 resin Substances 0.000 claims description 4
- 229920005989 resin Polymers 0.000 claims description 4
- 229940085605 saccharin sodium Drugs 0.000 claims description 4
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims description 4
- 229940013618 stevioside Drugs 0.000 claims description 4
- 235000019202 steviosides Nutrition 0.000 claims description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 3
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 3
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 claims description 3
- 239000003205 fragrance Substances 0.000 claims description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 2
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 claims description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- 229920001661 Chitosan Polymers 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- 229920001503 Glucan Polymers 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 239000004471 Glycine Substances 0.000 claims description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 2
- 241000195474 Sargassum Species 0.000 claims description 2
- 235000010358 acesulfame potassium Nutrition 0.000 claims description 2
- 229960004998 acesulfame potassium Drugs 0.000 claims description 2
- 239000000619 acesulfame-K Substances 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims description 2
- 239000008116 calcium stearate Substances 0.000 claims description 2
- 235000013539 calcium stearate Nutrition 0.000 claims description 2
- 239000008119 colloidal silica Substances 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 150000004676 glycans Chemical class 0.000 claims description 2
- 229940075507 glyceryl monostearate Drugs 0.000 claims description 2
- 239000008172 hydrogenated vegetable oil Substances 0.000 claims description 2
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 claims description 2
- 239000000391 magnesium silicate Substances 0.000 claims description 2
- 235000019792 magnesium silicate Nutrition 0.000 claims description 2
- 229910052919 magnesium silicate Inorganic materials 0.000 claims description 2
- ZADYMNAVLSWLEQ-UHFFFAOYSA-N magnesium;oxygen(2-);silicon(4+) Chemical compound [O-2].[O-2].[O-2].[Mg+2].[Si+4] ZADYMNAVLSWLEQ-UHFFFAOYSA-N 0.000 claims description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 claims description 2
- 229920001282 polysaccharide Polymers 0.000 claims description 2
- 239000005017 polysaccharide Substances 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 230000000873 masking effect Effects 0.000 abstract description 15
- 239000011247 coating layer Substances 0.000 abstract 2
- 239000003826 tablet Substances 0.000 description 111
- 239000000243 solution Substances 0.000 description 32
- 238000000034 method Methods 0.000 description 25
- 230000008673 vomiting Effects 0.000 description 21
- 206010047700 Vomiting Diseases 0.000 description 20
- 229960004106 citric acid Drugs 0.000 description 20
- 229960002194 oseltamivir phosphate Drugs 0.000 description 18
- 238000012360 testing method Methods 0.000 description 16
- 229940079593 drug Drugs 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 14
- 239000000047 product Substances 0.000 description 14
- 238000004090 dissolution Methods 0.000 description 11
- 239000000686 essence Substances 0.000 description 11
- 235000019658 bitter taste Nutrition 0.000 description 10
- 238000005516 engineering process Methods 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 241000272201 Columbiformes Species 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 239000002671 adjuvant Substances 0.000 description 7
- 239000002775 capsule Substances 0.000 description 7
- 238000001035 drying Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- 230000009967 tasteless effect Effects 0.000 description 6
- 241000712461 unidentified influenza virus Species 0.000 description 6
- 239000012530 fluid Substances 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 230000009965 odorless effect Effects 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- 235000009508 confectionery Nutrition 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000002572 peristaltic effect Effects 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 235000019605 sweet taste sensations Nutrition 0.000 description 4
- PHXWBVCRSNWZMT-JITBQSAISA-N (e)-but-2-enedioic acid;octadecanoic acid;sodium Chemical compound [Na].OC(=O)\C=C\C(O)=O.CCCCCCCCCCCCCCCCCC(O)=O PHXWBVCRSNWZMT-JITBQSAISA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000004744 fabric Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 229940023488 pill Drugs 0.000 description 3
- 230000001953 sensory effect Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000009747 swallowing Effects 0.000 description 3
- -1 1-ethyl propoxyl Chemical group 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000005352 clarification Methods 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 238000011031 large-scale manufacturing process Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000005181 root of the tongue Anatomy 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 201000010740 swine influenza Diseases 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000029386 Apodia Diseases 0.000 description 1
- 241001672694 Citrus reticulata Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 206010069767 H1N1 influenza Diseases 0.000 description 1
- 101000671819 Homo sapiens Ubiquitin carboxyl-terminal hydrolase 36 Proteins 0.000 description 1
- 208000002979 Influenza in Birds Diseases 0.000 description 1
- 229940123424 Neuraminidase inhibitor Drugs 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 208000025371 Taste disease Diseases 0.000 description 1
- 102100040109 Ubiquitin carboxyl-terminal hydrolase 36 Human genes 0.000 description 1
- 229920002522 Wood fibre Polymers 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 229910001854 alkali hydroxide Inorganic materials 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229960004543 anhydrous citric acid Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 206010064097 avian influenza Diseases 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940046011 buccal tablet Drugs 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 235000013574 canned fruits Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 238000000205 computational method Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 235000021185 dessert Nutrition 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 230000001037 epileptic effect Effects 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000021474 generally recognized As safe (food) Nutrition 0.000 description 1
- 235000021473 generally recognized as safe (food ingredients) Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000005213 imbibition Methods 0.000 description 1
- 208000037797 influenza A Diseases 0.000 description 1
- 208000037801 influenza A (H1N1) Diseases 0.000 description 1
- 208000037798 influenza B Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 235000019656 metallic taste Nutrition 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 239000006069 physical mixture Substances 0.000 description 1
- 238000011197 physicochemical method Methods 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 235000013324 preserved food Nutrition 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000003507 refrigerant Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000001835 salubrious effect Effects 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000002911 sialidase inhibitor Substances 0.000 description 1
- STFSJTPVIIDAQX-LTRPLHCISA-M sodium;(e)-4-octadecoxy-4-oxobut-2-enoate Chemical class [Na+].CCCCCCCCCCCCCCCCCCOC(=O)\C=C\C([O-])=O STFSJTPVIIDAQX-LTRPLHCISA-M 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000007885 tablet disintegrant Substances 0.000 description 1
- 229940061367 tamiflu Drugs 0.000 description 1
- 235000012976 tarts Nutrition 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 235000014101 wine Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Physiology (AREA)
- Zoology (AREA)
- Emergency Medicine (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (10)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310290328.7A CN103340835B (zh) | 2013-07-11 | 2013-07-11 | 一种适用于婴幼儿及儿童的口腔崩解片及其制备方法 |
PCT/CN2014/000835 WO2015003478A2 (zh) | 2013-07-11 | 2014-09-10 | 一种适用于婴幼儿及儿童的口腔崩解片及其制备方法 |
US14/992,040 US20160120802A1 (en) | 2013-07-11 | 2016-01-11 | Orally-disintegrating oseltamivir tablet and method for preparing the same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310290328.7A CN103340835B (zh) | 2013-07-11 | 2013-07-11 | 一种适用于婴幼儿及儿童的口腔崩解片及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103340835A true CN103340835A (zh) | 2013-10-09 |
CN103340835B CN103340835B (zh) | 2014-09-17 |
Family
ID=49275698
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310290328.7A Active CN103340835B (zh) | 2013-07-11 | 2013-07-11 | 一种适用于婴幼儿及儿童的口腔崩解片及其制备方法 |
Country Status (3)
Country | Link |
---|---|
US (1) | US20160120802A1 (zh) |
CN (1) | CN103340835B (zh) |
WO (1) | WO2015003478A2 (zh) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015003478A3 (zh) * | 2013-07-11 | 2015-03-05 | Sun Weidong | 一种适用于婴幼儿及儿童的口腔崩解片及其制备方法 |
CN104490801A (zh) * | 2014-11-27 | 2015-04-08 | 河南中帅医药科技股份有限公司 | 一种适用于婴幼儿及儿童的可压碎片及其制备方法 |
CN104940160A (zh) * | 2014-03-28 | 2015-09-30 | 广东东阳光药业有限公司 | 改进的磷酸奥司他韦固体组合物及其制备方法 |
CN105166306A (zh) * | 2015-08-27 | 2015-12-23 | 济南舜祥医药科技有限公司 | 一种海藻口香糖及其制备方法 |
CN106237337A (zh) * | 2016-08-05 | 2016-12-21 | 河南中帅医药科技股份有限公司 | 一种液体药物制剂用防腐组合物 |
CN106890146A (zh) * | 2015-12-18 | 2017-06-27 | 上海星泰医药科技有限公司 | 一种磷酸奥司他韦分散片及其制备方法 |
CN109999003A (zh) * | 2019-05-14 | 2019-07-12 | 湖南华纳大药厂股份有限公司 | 盐酸阿考替胺口崩片及其制备方法 |
CN113069423A (zh) * | 2020-01-04 | 2021-07-06 | 广东东阳光药业有限公司 | 一种巴洛沙韦酯口崩片及其制备方法 |
CN114159397A (zh) * | 2021-11-02 | 2022-03-11 | 北京微智瑞医药科技有限公司 | 一种磷酸奥司他韦微片及其制备方法和制剂 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6778051B2 (ja) * | 2016-08-18 | 2020-10-28 | 沢井製薬株式会社 | オセルタミビルリン酸塩含有医薬組成物 |
EP3673901A4 (en) * | 2017-08-21 | 2021-05-19 | Nipro Corporation | PARTICLES OF A PHARMACEUTICAL COMPOSITION, ORAL DISCLOSURE PREPARATION THEREOF AND PROCESS FOR THE PREPARATION OF PARTICLES OF A PHARMACEUTICAL COMPOSITION |
IL262768B (en) * | 2018-11-04 | 2020-08-31 | Ambrosia Supherb Ltd | Chewable tablet and method for its preparation |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010143207A1 (en) * | 2009-06-11 | 2010-12-16 | Rubicon Research Private Limited | Taste-masked oral formulations of influenza antivirals |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050175689A1 (en) * | 2003-10-27 | 2005-08-11 | Yamanouchi Pharmaceutical Co., Ltd. | Coated fine particles containing drug for intrabuccally fast disintegrating tablet |
CN102172348B (zh) * | 2011-02-12 | 2013-02-20 | 北京博康宁生物医药科技有限公司 | 固体的磷酸奥司他韦药物组合物 |
CN103340835B (zh) * | 2013-07-11 | 2014-09-17 | 河南中帅医药科技股份有限公司 | 一种适用于婴幼儿及儿童的口腔崩解片及其制备方法 |
-
2013
- 2013-07-11 CN CN201310290328.7A patent/CN103340835B/zh active Active
-
2014
- 2014-09-10 WO PCT/CN2014/000835 patent/WO2015003478A2/zh active Application Filing
-
2016
- 2016-01-11 US US14/992,040 patent/US20160120802A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010143207A1 (en) * | 2009-06-11 | 2010-12-16 | Rubicon Research Private Limited | Taste-masked oral formulations of influenza antivirals |
Non-Patent Citations (1)
Title |
---|
代琴等: "口腔崩解片辅料选用研究", 《中国医药指南》 * |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015003478A3 (zh) * | 2013-07-11 | 2015-03-05 | Sun Weidong | 一种适用于婴幼儿及儿童的口腔崩解片及其制备方法 |
CN104940160B (zh) * | 2014-03-28 | 2019-06-07 | 广东东阳光药业有限公司 | 改进的磷酸奥司他韦固体组合物及其制备方法 |
CN104940160A (zh) * | 2014-03-28 | 2015-09-30 | 广东东阳光药业有限公司 | 改进的磷酸奥司他韦固体组合物及其制备方法 |
CN104940160B9 (zh) * | 2014-03-28 | 2019-09-27 | 广东东阳光药业有限公司 | 改进的磷酸奥司他韦固体组合物及其制备方法 |
CN104490801A (zh) * | 2014-11-27 | 2015-04-08 | 河南中帅医药科技股份有限公司 | 一种适用于婴幼儿及儿童的可压碎片及其制备方法 |
CN105166306A (zh) * | 2015-08-27 | 2015-12-23 | 济南舜祥医药科技有限公司 | 一种海藻口香糖及其制备方法 |
CN106890146A (zh) * | 2015-12-18 | 2017-06-27 | 上海星泰医药科技有限公司 | 一种磷酸奥司他韦分散片及其制备方法 |
CN106237337A (zh) * | 2016-08-05 | 2016-12-21 | 河南中帅医药科技股份有限公司 | 一种液体药物制剂用防腐组合物 |
CN106237337B (zh) * | 2016-08-05 | 2019-11-08 | 河南中帅医药科技股份有限公司 | 一种液体药物制剂用防腐组合物 |
CN109999003A (zh) * | 2019-05-14 | 2019-07-12 | 湖南华纳大药厂股份有限公司 | 盐酸阿考替胺口崩片及其制备方法 |
CN109999003B (zh) * | 2019-05-14 | 2022-03-25 | 湖南华纳大药厂股份有限公司 | 盐酸阿考替胺口崩片及其制备方法 |
CN113069423A (zh) * | 2020-01-04 | 2021-07-06 | 广东东阳光药业有限公司 | 一种巴洛沙韦酯口崩片及其制备方法 |
CN114159397A (zh) * | 2021-11-02 | 2022-03-11 | 北京微智瑞医药科技有限公司 | 一种磷酸奥司他韦微片及其制备方法和制剂 |
Also Published As
Publication number | Publication date |
---|---|
WO2015003478A2 (zh) | 2015-01-15 |
CN103340835B (zh) | 2014-09-17 |
WO2015003478A3 (zh) | 2015-03-05 |
US20160120802A1 (en) | 2016-05-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103340835B (zh) | 一种适用于婴幼儿及儿童的口腔崩解片及其制备方法 | |
TW586941B (en) | Quickly disintegratable pharmaceutical composition | |
CN103315965B (zh) | 一种适用于婴幼儿及儿童的口服固体颗粒及其制备方法 | |
WO2018077310A1 (zh) | 一种含维生素c钠的泡腾片及其制备方法 | |
JP4555407B2 (ja) | 用時調製漢方・生薬製剤 | |
US8569375B2 (en) | Compositions | |
JP2010540588A (ja) | 口腔内崩壊錠剤 | |
WO2023193745A1 (zh) | 一种右美沙芬奎尼丁口崩片及其应用 | |
JP2019189635A (ja) | 安定性に優れた固形製剤 | |
CN104490801A (zh) | 一种适用于婴幼儿及儿童的可压碎片及其制备方法 | |
Chandrawanshi Mayuri et al. | A review on medicated lozenges | |
TWI706785B (zh) | 安神助眠的組合物及其製備方法與應用 | |
Lakshmi et al. | Formulation and evaluation of domperidone candy lozenges | |
WO2016086557A1 (zh) | 一种维d钙组合物咀嚼片及其制备方法 | |
US10813898B2 (en) | Solid dosage forms of vigabatrin | |
JP2010154769A (ja) | ポリフェノール含有顆粒またはポリフェノール含有チュアブル錠剤およびその製造方法 | |
MXPA06012399A (es) | Pastilla para la administracion del dextrometorfano. | |
JP6590436B1 (ja) | 安定性に優れた固形製剤 | |
Pravalika et al. | Formulation and evaluation of theophylline lozenges | |
Saxena et al. | A review on fast dissolving tablets | |
WO2017109547A1 (es) | Premezcla y composición farmacéutica para la administración oral de memantina como suspensión permanente o de preparación previa a la administración al paciente y optativamente por sonda de alimentación enteral y procedimientos correspondientes | |
US20220110900A1 (en) | Solid nutrient compositions and associated methods | |
WO2003026619A1 (fr) | Granules presentant des proprietes de dosage ameliorees | |
US11654108B1 (en) | Sennoside medicated chews | |
Rao et al. | Design and Development of Tramadol Hydrochloride Lozenges for Pediatrics |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: ZHONGSHUAI PHARMACEUTICAL SCIENCE AND TECHNOLOGY I Free format text: FORMER OWNER: SUN WEIDONG Effective date: 20140124 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20140124 Address after: 18, building 7, block A1, 450001 Holly Road, Gaoxin District, Henan, Zhengzhou Applicant after: ZHONGSHUAI PHARMACEUTICAL SCI & TECH INCORPORATED CO., LTD. Address before: 18, building 7, building A, bio Pharmaceutical Industrial Park, 450001 Holly Road, Gaoxin District, Henan, Zhengzhou Applicant before: Sun Weidong |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant |